MAY 15, 2019 12:00 PM EDT

Unraveling the legacy and future of Hepatitis B Diagnosis: Clinical impact of conventional molecular tests and HBV-RNA to monitor hepatic infections

  • Head of Infectious Disease Research, Diagnostics at Abbott

      Gavin A. Cloherty, Ph.D., is head of Infectious Disease Research for Abbott's diagnostics business. He provides scientific leadership in the area of infectious disease diagnostics by conducting groundbreaking clinical studies on hepatitis and HIV and developing new tests. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes. Gavin has more than 20 years of experience with Abbott and leads a team of scientists in the study of the viral diversity of HIV and hepatitis. His expertise is sought after globally through his established partnerships with commercial organizations, ministries of health, government agencies and academic institutions, such as the Centers for Disease Control and Prevention (CDC) and National Institutes of Health's AIDS Clinical Trial Group (ACTG) and Hepatitis B Research Network (HBRN). He has worked with the Republic of Georgia to help eradicate hepatitis C in the country, and is looking to expand these efforts to other regions of the world severely impacted by this disease. As a senior research scientist, Gavin assisted in the development and design of the Abbott Molecular RealTime tests and m2000 system. Throughout his career Gavin has published numerous studies, abstracts and posters. In addition to his impressive list of publications he also has been invited to speak at conferences around the world. Gavin graduated from the National University of Ireland, Galway, where he received his Ph.D. in molecular biology and a Bachelor of Science in microbiology and zoology. Gavin is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease. He also is a contributor to multiple editorial boards, including the Journal of Clinical Microbiology and Journal of Clinical Virology.


    DATE: May 15, 2019
    TIME: 9:00am PDT, 11:00am CDT, 12:00pm EDT

    Hepatitis B infections remain a significant global healthcare burden resulting in 887,000 deaths in 2015. Clinical laboratories can have a measurable impact in improving liver disease care while maximizing healthcare systems efficiencies through the application of high-quality diagnostic technologies. Abbott Laboratories legacy of innovation in hepatitis diagnostics spans decades and continues with the development of an automated assay for the detection of serum HBV pregenomic RNA (pgRNA). Serum HBV pgRNA has been proposed as a marker of HBV cccDNA activity and may be a useful clinical biomarker in evaluating chronic hepatitis B patient response to current nucleoside analogue therapy and aid in the development of novel therapeutic regimens. pgRNA kinetics in conjunction with other molecular and serologic tests may provide insights which aid in the staging and management of people with chronic HBV.

    Learning Objectives:

    • Understand the impact and healthcare burden of Global Hepatitis B Infections.
    • Discover how efforts in assay development led to pregenomicRNA (pgRNA) as an indicator of Hepatis B activity.
    • Comprehend the potential applications of pgRNA in therapy response monitoring.


    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 18, 2020 8:00 AM PST
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 16, 2020 8:00 AM PST
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    APR 01, 2021 8:00 AM PDT
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAY 15, 2019 12:00 PM EDT

    Unraveling the legacy and future of Hepatitis B Diagnosis: Clinical impact of conventional molecular tests and HBV-RNA to monitor hepatic infections


    Laboratory Testing

    Molecular Diagnostics

    Infectious Disease

    Molecular Biology


    Clinical Diagnostics


    Clinical Chemistry




    Clinical Research

    Cancer Research

    Cell Biology



    North America73%



    South America3%



    Registration Source

    Website Visitors46%

    Email Promotions38%

    WAVE Newsletter Promotion11%

    Trending Newsletter Promotion1%

    Client/Sponsor Promotions1%


    Job Title

    Medical Laboratory Technician27%

    Lab Management15%

    Clinical Laboratory Scientist15%

    Facility/Department Manager9%


    Research Scientist5%


    Medical Doctor/Specialist5%









    Clinical Laboratory21%

    Academic Institution10%

    Biotech Company5%

    Medical Center4%


    Medical Device Company3%

    Research Institute3%

    Diagnostic Company3%


    Life Science Company2%

    Industrial Company2%

    Non-Profit Organization2%

    Medical School1%


    Show Resources
    Loading Comments...
    Show Resources
    • See more